Compare PHGE & MEGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHGE | MEGL |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | Israel | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.6M |
| IPO Year | N/A | 2022 |
| Metric | PHGE | MEGL |
|---|---|---|
| Price | $2.44 | $1.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | ★ 118.2K | 25.1K |
| Earning Date | 11-12-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,296,394.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $1.02 |
| 52 Week High | $22.06 | $5.52 |
| Indicator | PHGE | MEGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 52.52 |
| Support Level | $4.10 | $1.23 |
| Resistance Level | $6.03 | $1.30 |
| Average True Range (ATR) | 0.52 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 36.73 | 52.78 |
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.